News
VXRT
0.7289
-2.68%
-0.0201
Vaxart Announces Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers; Long-Term Goal Is To Provide Protection To Infants Through Passive Antibody Transfer
Antibody rise observed in lactating mothers and in their breast milk. Antibodies to norovirus rose on average 4.0 fold in the breast milk of mothers who received the vaccine. Long-term goal is to provide protection to infants through passive antibody transfer. No approved vaccine against norov virus sickens 21 million people in the United States each year.
Benzinga · 4d ago
VAXART INC - ANTIBODY RISE OBSERVED IN LACTATING MOTHERS AND IN THEIR BREAST MILK
Reuters · 4d ago
Weekly Report: what happened at VXRT last week (0422-0426)?
Weekly Report · 5d ago
Weekly Report: what happened at VXRT last week (0415-0419)?
Weekly Report · 04/22 10:07
Weekly Report: what happened at VXRT last week (0408-0412)?
Weekly Report · 04/15 10:02
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Investorplace · 04/09 20:30
Weekly Report: what happened at VXRT last week (0401-0405)?
Weekly Report · 04/08 10:05
Weekly Report: what happened at VXRT last week (0325-0329)?
Weekly Report · 04/01 10:04
Weekly Report: what happened at VXRT last week (0318-0322)?
Weekly Report · 03/25 10:06
Press Release: Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to the Company's new President and Chief Executive Officer, Steven Lo, effective March 18, 2024. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines.
Dow Jones · 03/20 12:00
Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements
Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Vaxart (VXRT) with a price target of $2.00. The company's lead norovirus vaccine candidate is nearing the end of Phase II trials with promising immunogenicity and efficacy data.
TipRanks · 03/20 11:25
Weekly Report: what happened at VXRT last week (0311-0315)?
Weekly Report · 03/18 10:05
VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023
Vaxart reported earnings per share of -12 cents for the fourth quarter of 2023. The company reported revenue of $3.25 million. This was 159.60% better than the analyst estimate for revenue. Vaxart also reported results for the third quarter of 2018.
Investorplace · 03/15 00:55
Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M
Earnings News Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M. Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
Seeking Alpha · 03/14 20:15
Options Volatility and Implied Earnings Moves Today, March 14, 2024
Several major companies are expected to report earnings today. Adobe (ADBE), Dollar General (DG) and Weibo (WB) are among the companies. TipRanks shows you the expected earnings move, based on options prices. The list is divided by the timing of each company's earnings release.
TipRanks · 03/14 12:05
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: Adobe, Ulta Beauty, Skillz and Wheaton Precious Metals Corp. Other notable earnings slated for release after Thursday's close include: ZUMZ, ULTA and Blink Charging Co. Other companies with major earnings scheduled after the close of business on Thursday.
Seeking Alpha · 03/13 21:35
Vaxart FY 2023 Earnings Preview
Vaxart (NASDAQ:VXRT) is scheduled to announce FY earnings results on Thursday, March 14th. The consensus EPS Estimate is -$0.61 and the consensus revenue estimate is $5.21M. Over the last 2 years, VXRT has beaten estimates 38% of the time.
Seeking Alpha · 03/13 21:35
Vaxart's Earnings: A Preview
Vaxart is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Analysts estimate the company will report an earnings per share of $-0.14. Last quarter the company beat EPS by $0.07. Shares of Vaxart were trading at $1.14 as of March 12.
Benzinga · 03/13 19:01
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
NASDAQ · 03/11 12:03
More
Webull provides a variety of real-time VXRT stock news. You can receive the latest news about Vaxart Inc through multiple platforms. This information may help you make smarter investment decisions.
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.